Solid organ graft-versus-host disease in a recipient of a COVID-19 positive liver graft

[1]  S. Nishida,et al.  Solid organ transplantation from COVID positive donors in the United States: Analysis of United Network for Organ Sharing database , 2022, Transplant infectious disease : an official journal of the Transplantation Society.

[2]  J. Dipersio,et al.  The use of ruxolitinib for acute graft‐versus‐host disease developing after solid organ transplantation , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  M. Kaminski,et al.  Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. , 2019, The Lancet. Haematology.

[4]  A. Meves,et al.  Clinical and histopathologic manifestations of solid organ transplantation‐associated graft‐versus‐host disease involving the skin: A single‐center retrospective study , 2018, Journal of cutaneous pathology.

[5]  A. Meves,et al.  Dermatologic manifestations of solid organ transplantation–associated graft‐versus‐host disease: A systematic review , 2017, Journal of the American Academy of Dermatology.

[6]  B. Blazar,et al.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. , 2017, The New England journal of medicine.

[7]  E. Smith.  Hematologic disorders after solid organ transplantation. , 2010, Hematology. American Society of Hematology. Education Program.

[8]  G. Ayers,et al.  Endoscopic Biopsy Diagnosis of Acute Gastrointestinal Graft-Versus-Host Disease: Rectosigmoid Biopsies Are More Sensitive Than Upper Gastrointestinal Biopsies , 2008, The American Journal of Gastroenterology.

[9]  G. Klintmalm,et al.  Liver transplant-associated graft-versus-host disease , 2003, Transplantation.